Diligence memo · auto-generated · as of July 2, 2026

Locus Biosciences, Inc.

Locus Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Locus Biosciences, Inc. operates in Biotechnology, based in Morrisville.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Locus Biosciences, Inc. has raised $46M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $20M on 2020-04-08.

Most recent recorded round closed around 2022-01-28.

Valuation (modeled)modeled

Provath models Locus Biosciences, Inc. at approximately $213M (range $21M–$607M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.27× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 10 months.

Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).

Modeled value ranks above 73% of those peers.

Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.